Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc (ALXO, Financial), sold 12,000 shares of the company on May 13, 2024. The transaction was filed on May 15, 2024, as reported in the SEC Filing.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway. The company's lead candidate, evorpacept, is designed to enhance the body's immune response to fight cancer.
Over the past year, the insider has sold a total of 13,605 shares and has not purchased any shares. This recent sale is part of a broader trend observed at ALX Oncology Holdings Inc, where there have been 10 insider sells and only 1 insider buy over the past year.
On the date of the latest transaction, shares of ALX Oncology Holdings Inc were priced at $15.94, resulting in a market cap of approximately $782.544 million.
Investors and stakeholders often monitor insider transactions as they can provide valuable insights into a company's internal perspective on its financial health and future prospects. For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, interested parties are encouraged to visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
